RISK ASSESSMENT AND MANAGEMENT TO IMPROVE PARENTERAL NUTRITION SAFETY
5PSQ-112
UPDATED MEDICATION LISTS – A PROBLEM ANALYSIS WITH IMPROVEMENT SUGGESTIONS
5PSQ-101
ONCOLYTIC VIRUSES RISK AND CONTROL ASSESSMENT: TALIMOGENE LAHERPAREPVEC EXPERIENCE
5PSQ-097
TOXICITY ASSOCIATED WITH GENE POLYMORPHISMS IN PATIENTS WITH COLORECTAL CANCER, TREATED WITH FLUOROPYRIMIDINES AND ANALOGUES, IRINOTECAN AND PLATINUM COORDINATION COMPLEXES
5PSQ-096
EFFICACY AND SECURITY OF PLASMA RICH IN GROWTH FACTORS EYE DROPS FOR THE TREATMENT OF OCULAR SURFACE DISEASES
5PSQ-088
PATHOPHYSIOLOGY OF OROPHARYNGEAL DYSPHAGIA IN DEMENTIA PATIENTS TAKING ANTIPSYCHOTICS USING A VIDEOFLUOROSCOPY STUDY
5PSQ-087
EVIDENCE AND DECISION ALGORITHM FOR THE WITHDRAWAL OF ANTIPSYCHOTIC TREATMENT IN THE ELDERLY WITH DEMENTIA AND NEUROPSYCHIATRIC SYMPTOMS
5PSQ-086
OPTIMISATION OF STOCK OF LEVODOPA/CARBIDOPA INTESTINAL GEL BY USING A SEMI-AUTOMATIC PLANNING SYSTEM
5PSQ-082
CYCLOPHOSPHAMIDE THERAPY IN CHILDREN WITH NEPHROTIC SYNDROME
5PSQ-078
SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS AND PSORIATIC ARTHRITIS IN CLINICAL PRACTICE
5PSQ-073
REVIEW OF METABOLIC AND ELECTROLYTIC ALTERATIONS IN PATIENTS WITH ENTERAL NUTRITION
5PSQ-072
TOLERANCE PROFILE OF PLATINUM SALTS IN ANTICANCER CHEMOTHERAPY: A PROSPECTIVE STUDY
5PSQ-069
BASAL CELL EPITHELIOMA INDUCED BY IBRUTINIB: TWO CASE REPORTS
5PSQ-067
ANALYSIS OF ANTINEOPLASTIC DRUGS PREPARATION ERRORS AS A FIRST STEP TO IMPROVE THE QUALITY OF THE PROCESS
5PSQ-065
CARDIOVASCULAR TOXICITY INDUCED BY TARGETED AGENTS
